Sai Parenterals IPO: Check Price Band, GMP, Risk Factors and More

Synopsis: Sai Parenterals’ mainboard IPO brings a diversified pharma formulations and CDMO player to the primary market. The company plans to use the issue proceeds for capacity expansion, a new R&D centre, debt repayment, working capital, and overseas investment, while investors will track its growth, valuation, and execution of expansion plans closely.

Sai Parenterals Limited, a pharmaceutical formulations company with operations across branded generics and CDMO services, is entering the capital markets through its mainboard IPO. Backed by manufacturing facilities, export presence, and improving financial performance, the company aims to strengthen operations through fresh funds. The issue places focus on its growth prospects, promoter backing, and expansion-led business strategy.

Sai Parenteral’s IPO is a book-built issue worth Rs 408.79 crore, comprising a fresh issue of 73 lakh shares, aggregating to Rs 285 crore, and an offer for sale of 32 lakh shares worth Rs 123.79 crore. The issue will open for subscription on March 24, 2026, and close on March 27, 2026. The company has fixed a price band of Rs 372 to Rs 392 per share, with investors able to bid within this range during the subscription period.

GMP of Sai Parentals IPO

As of 23 March 2026, Sai Parenteral’s shares are expected to list around Rs 392 according to the grey market, indicating a 0% premium over the issue price. This suggests a flat listing expectation, reflecting balanced investor interest and a neutral sentiment in the unofficial market ahead of the company’s official stock market debut.

Objective of the IPO

The company plans to use the proceeds of the proposed IPO for expanding and strengthening its business operations. Out of the total proceeds, Rs 110.80 crore are proposed to be utilised for capacity expansion and upgradation of its manufacturing facilities. Another amount of Rs 18.02 crore is proposed to be utilised for creating a new research and development centre.

Further, the company proposes to utilise Rs 14.30 crore for repayment or prepayment of certain outstanding borrowings and Rs 33 crore for working capital requirements. Another amount of Rs 35.64 crore is proposed to be utilised for investment in its wholly owned subsidiary, Sai Parenterals Pte Limited, Singapore, in connection with the proposed acquisition of Noumed Pharmaceuticals Pty Limited, Australia.

About the company 

Sai Parenterals Limited, incorporated in the year 2001, is a diversified pharmaceutical formulations company offering research, development, and manufacturing capabilities. The company operates in two main segments: branded generic formulations and contract development and manufacturing organisation (CDMO) services. These segments serve both domestic and international markets. The company has a wide scope of therapeutic segments, including cardiovascular, antidiabetics, respiratory, antibiotics, gastroenterology, dermatology, and nutraceutical segments. 

These products are available in various dosage forms, such as injectables, tablets, capsules, and ointments. The company has developed a strong manufacturing base, with five plants in India, primarily in Hyderabad. These plants are WHO-GMP and internationally accredited. The company has further expanded its international presence after entering exports in FY23. 

These exports are to countries such as Australia, New Zealand, Southeast Asia, the Middle East, and Africa. The company has a diversified base of customers, including government institutions, hospitals, and pharmaceutical companies. Sai Parenterals is aiming to grow in the generic and CDMO segments.

Promoter Holding

The promoter’s stake in Sai Parenterals prior to the IPO stands at 61.23%, which will reduce to 51.2% after the IPO. This reduction in stake is due to the issue of fresh equity shares. However, it is clear that even after the reduction in stake due to the IPO issue, the promoter’s stake in the business remains significant.

The pre-IPO EPS of Sai Parenterals stands at Rs 5.43, whereas the issue is priced at a P/E of 72.19 times its pre-issue earnings. At its highest point, Sai Parenterals’ market capitalisation stands at Rs 1,731.83 crore. The promoter of Sai Parenterals comprises Anil Kumar Karusala, Vijitha Gorrepati, and Karusala Aruna.

Financial Performance 

The financial performance of Sai Parenterals indicates steady growth in the company’s financials. Total income has grown from Rs 97.03 crore in FY23 to Rs 155.18 crore in FY24 and then to Rs 163.74 crore in FY25. In the period ended 30th September 2025, the total income was Rs 89.43 crore. Thus, the total income of the company has continued to grow in the current financial year as well.

The profitability of the company has also grown significantly in the past few years. Profit after tax has grown from Rs 4.38 crore in FY23 to Rs 8.42 crore in FY24 and then to Rs 14.43 crore in FY25. In the half-year ended 30th September 2025, the profit after tax was Rs 7.76 crore. In addition, EBITDA has grown from Rs 31.70 crore in FY24 to Rs 39.44 crore in FY25. Moreover, the net worth of the company has grown significantly to Rs 209.37 crore as of September 2025. In addition, total borrowings of the company have decreased to Rs 76.07 crore from Rs 118.79 crore in FY24.

Competitive Strengths

• A diversified pharmaceutical formulations company with a presence in both branded generic formulations and CDMO products and services.
• Broad product portfolio across multiple therapeutic areas such as cardiovascular, neuropsychiatry, anti-diabetic, respiratory, antibiotics, gastroenterology, vitamins, minerals and supplements, analgesics, and dermatology.
• Wide dosage-form capabilities, including injectables, tablets, capsules, liquid orals, and ointments.
• Strong manufacturing base with five facilities in India, including accredited plants in Hyderabad and a GMP-certified facility in Ongole through its subsidiary.
• Expanding international presence, with exports to Australia, New Zealand, Southeast Asia, the Middle East, and Africa.
• Established distribution network in India and overseas, supported by experienced promoters and senior management. 

Risk Factors

• The pharmaceutical business remains exposed to regulatory and compliance risks, especially across domestic and export markets.
• High dependence on manufacturing facilities, where any disruption in operations or approvals may affect performance.
• Faces competition in both the formulations and CDMO segments, which can put pressure on growth and margins.
• Expansion plans, including capacity addition, a new R&D centre, and overseas acquisition-related investment, carry execution risk.
• Since this is the company’s first public issue, there is no formal market history for its shares, and post-listing price discovery may remain uncertain. 

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

.

The post Sai Parenterals IPO: Check Price Band, GMP, Risk Factors and More appeared first on Trade Brains.